Effect of Astragalus Polysaccharide on p38 MAPK Signal Pathway of Rats with Myocardial Ischemic Reperfusion Injury

XU Bing 1; LIU Bei 1; ZHU Haiyan 2; ZHANG Ying 3; ZHU Lingqun 1; CHEN Lixin 4

doi:10.13288/j.11-2166/r.2012.01.029

您当前的位置：

首页 >

文章列表页 >

Effect of Astragalus Polysaccharide on p38 MAPK Signal Pathway of Rats with Myocardial Ischemic Reperfusion Injury

更新时间：2021-11-17

- Effect of Astragalus Polysaccharide on p38 MAPK Signal Pathway of Rats with Myocardial Ischemic Reperfusion Injury
- Journal of Traditional Chinese Medicine Vol. 53, Issue 1, Pages: 52-54(2012)
- 作者机构：
  
  1. 北京中医药大学东直门医院
  2. 北京师范大学中药资源与资源药物研究所
  3. 北京市宣武中医院心内科
- 作者简介：
- 基金信息：
- DOI：10.13288/j.11-2166/r.2012.01.029
  CLC： R285.5
- Published：2012
- 稿件说明：
移动端阅览
[1]徐冰,刘蓓,朱海燕,张莹,朱陵群,陈立新.黄芪多糖对大鼠心肌缺血再灌注损伤心肌p38信号通路的影响[J].中医杂志,2012,53(01):52-54.

XU Bing 1, LIU Bei 1, ZHU Haiyan 2, et al. Effect of Astragalus Polysaccharide on p38 MAPK Signal Pathway of Rats with Myocardial Ischemic Reperfusion Injury[J]. Journal of Traditional Chinese Medicine2012, 53(1): 52-54.
[1]徐冰,刘蓓,朱海燕,张莹,朱陵群,陈立新.黄芪多糖对大鼠心肌缺血再灌注损伤心肌p38信号通路的影响[J].中医杂志,2012,53(01):52-54. DOI： 10.13288/j.11-2166/r.2012.01.029.

XU Bing 1, LIU Bei 1, ZHU Haiyan 2, et al. Effect of Astragalus Polysaccharide on p38 MAPK Signal Pathway of Rats with Myocardial Ischemic Reperfusion Injury[J]. Journal of Traditional Chinese Medicine2012, 53(1): 52-54. DOI： 10.13288/j.11-2166/r.2012.01.029.

摘要

目的研究黄芪多糖（APS）对大鼠缺血再灌注损伤心肌的作用。方法将70只Wistar大鼠随机分为假手术组、缺血再灌注模型组、APS低剂量组、APS高剂量组、p38MAPK阻断剂（SB203580）组、APS低剂量+SB203580组、APS高剂量+SB203580组

每组10只。采用结扎左冠状动脉前降支复制缺血再灌注损伤模型。各组大鼠尾声静脉注射相应药物

每日1次

连续给药30天。氯化硝基四氮唑蓝染色后

测量心肌梗死面积及梗死重量。结果与模型组比较

除APS低剂量组外

其他各给药组均可显著减少缺血再灌注心肌的梗死面积和重量（P<0.05或P<0.01）

并且APS高剂量联合SB203580组治疗效果明显优于各单药治疗组（P<0.05）。结论 APS能够明显改善大鼠心肌缺血再灌注损伤

APS高剂量与p38MAPK阻断剂联合应用对抑制再灌注损伤具有协同作用

其机制可能与其部分抑制p38MAPK信号通路

阻断其介导的炎症反应对心肌的损伤有关。

Abstract

Objective To study the effect of astragalus polysaccharide （APS） on myocardial ischemic reperfusion injury in rats.Methods Seventy Wistar rats were randomized into sham operation group

model group

APS low dose group

APS high dose group

p38MAPK SB203580 group

APS low dose & SB203580 group

and APS high dose & SB203580 group

with 10in each.The left anterior descending coronary artery was ligated to make models of ischemic reperfusion injury.The corresponding medicine was injected via tail vein of each group of rats

once a day

30 days in total.The size and weight of the infarcted myocardium were measured after nitro blue tetrazolium chloride dyeing.Results Infarcted size and weight of the ischemic reperfusion myocardium were lower in all groups except the APS low dose group than in the model group （P<0.05 or P<0.01）.Furthermore

the APS high dose &SB203580 group had better effect than other groups （P<0.05）.Conclusion APS is effective in improving the pathological condition of myocardial ischemic reperfusion injury in rats

and the combination of APS high dose with SB203580 has a synergic function in inhibiting the reperfusion injury.The mechanism may be related to its effect in inhibiting the p38MAPK signal pathway and blocking the induced inflammatory reaction on myocardium.

关键词

Keywords

references

查看原文

Views

607

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Research on the Correlation Between "Tiangui （天癸）" and Female Reproductive Genetic Diseases

Challenges and Recommendations for Implementing Key Technologies in Decentralized Clinical Trials of Traditional Chinese Medicine

A Preliminary Discussion on the Method of Regulating Qi and Calming the Mind

Similarities and Differences between Myofascial Trigger Points and Sinew Knot：from the Perspective of the Channel Sinew Theory

Current Status and Strategic Recommendations for Randomized Controlled Trials on Functional Dyspepsia-Irritable Bowel Syndrome Comorbidity：from a Real-World Research Perspective

Related Author

No data

Related Institution

No data

Address：No.16, Nanxiao street, Dongzhimen, Dongcheng District, Beijing Postal code：100700
Tel：010-64035632 Email：jtcmcn@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19 京公网安备11010102007558号
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰